Patent · US Active

Pyrimidinone derivatives as SHP2 antagonists

US11001561B2 · kind B2 · utility

0Cited by

2References

19Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Catherine Jorand-Lebrun · Arlington, US
Roch Boivin · North Chelmsford, US
Theresa L. Johnson · Salem, US
Yanping Wang · Beijing, CN
Yufang Xiao · Lexington, US
Xiaoling Chen · Sharon, US
Nina Linde · Frankfurt am Main, DE
Doreen Musch · Darmstadt, DE
Deepak Kumar · Delhi, IN

Key dates

Filing date	Apr 8, 2020
Grant date	May 11, 2021
Priority date	—
Expiry date	Apr 8, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D491/20
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The invention relates to pyrimidinone derivatives of the general Formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.